Abstracts

IMMUNE OMIC PROFILES TO DISTINGUISH TUBERCULOSIS AMONG ADVANCED HIV ADULTS IN INDIA

Background: Diagnosis of tuberculosis (TB) in people with HIV (PWH) with significant immunosuppression remains a challenge. Integration of flow cytometry, cytokine, and gene expression data is a promising approach for developing diagnostic TB biomarkers but such “multi-omic” analysis remains poorly explored. Methods: We enrolled 30 adults with advanced HIV(CD4< 100cells/mm3) in India; 16 with microbiologically…

RANDOMIZED EVALUATION OF THE IMPACT OF STI POINT-OF-CARE TESTING ON PrEP INITIATION

Background: Pre-exposure prophylaxis (PrEP) programs present a platform for integrating curable sexually transmitted infection (STI) testing and treatment. Point-of-care (POC) STI testing has been hypothesized to influence PrEP use, but data are few, especially in pregnancy. We evaluated the impact of POC STI testing compared to standard-of-care (SOC) STI syndromic management on PrEP initiation and…

URACIL TREATMENT DOES NOT INCREASE SUSCEPTIBILITY TO RECTAL SIV INFECTION

Background: The intestinal microbiome of men who have sex with men (MSM) is distinct as compared to non-MSM and is suggested to increase susceptibility to rectal HIV infection. Indeed, we recently demonstrated that dysbiosis-associated disruptions in host antimicrobial immunity increase susceptibility to rectal SIVmac239X in rhesus macaques (RMs; Macaca mulatta). Central to the susceptibility-associated antimicrobial…

EMERGING INTEGRASE INHIBITOR HIV DRUG RESISTANCE MUTATIONS: TANZANIAN NATIONAL SURVEY

Background: In 2019, a potent integrase strand transfer inhibitor (INSTI), dolutegravir (DTG) was made available for public use in Tanzania. However, the switching was conducted without confirmation of the virological suppression, hence the treatment success has not been fully appreciated. HIV drug resistance (HIVDR) including against DTG could be implicated in the notable suboptimal viral…

PROGRESS TOWARDS THE ELIMINATION OF CERVICAL CANCER AMONG WOMEN LIVING WITH HIV

Background: Acquisition and persistence of carcinogenic human papillomavirus (HPV) infections and the incidence of precancerous lesions and invasive cervical cancers are all increased for women living with HIV (WLHIV) compared with their HIV-negative peers. To reduce new cervical cancer cases among WLHIV, the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) supports regular cervical cancer…

DISCOVERING SUBGROUPS WITH LARGER WEIGHT GAIN WHEN TAKING DOLUTEGRAVIR

Background: Clinical trials have shown that dolutegravir (DTG)-containing antiretroviral therapy results in larger weight gains than other antiretroviral therapies (ARTs). Not all people are expected to have the same risk for increased weight gain with DTG-containing ARTs. Discovering subgroups for whom DTG is more likely to cause substantial weight gain allows treatment recommendations to be…

NOVEL BISPECIFIC ENGAGER REDIRECTS CMV-SPECIFIC CTL TO ELIMINATE HIV-INFECTED CELLS

Background: We developed a novel biologic (RediTac) to selectively activate and expand virus-specific memory CD8 T cells (CTLs), redirect them to eliminate HIV-infected cells, and thereby eliminate reactivated latent HIV-infected cells. RediTac employs a bispecific Fc-fusion protein scaffold to dimerize HLA-A2 pMHC linked to HIV bNAb scFvs. The pMHC presents a tethered viral peptide for…